Genlantis, a division of Gene Therapy Systems, Inc. is located in San Diego, California. Genlantis designs, develops and commercializes biological reagents for life scientists worldwide. The Company is focused on the development of protein expression tools as well as efficient delivery technologies for both in vitro and in vivo applications.
Genlantis lab Genlantis offers a comprehensive line of specialty products that include the GenePORTER® transfection products for gene delivery and plasmid DNA, GeneSilencer® reagent useful in the delivery of siRNA for gene suppression in mammalian cells, NeuroFECT® reagent for optimized transfection of primary neurons, and NeuroPure® primary neuronal cells.
In addition, our patented Tap Express® and Xi-Clone® Instant Enzymeless PCR Cloning technologies are available for licensing. These patented technologies offer scientists the ability to design experiments involving hundreds or even thousands of proteins simultaneously at a very reasonable cost. They allow the rapid generation of proteins from complex infectious organisms such as malaria, tuberculosis, anthrax, smallpox virus, Chlamydia, helicobacter, and many more.
Scanning the Vaccinia Proteome for Anti Smallpox Antigens The major goal of this project is to produce the complete vaccinia proteome from ACAM2000 strain, and use it to identify immunogenic antigens to develop diagnostics, therapeutics and a DNA or protein subunit vaccine against smallpox. Collaborators include Dr. Luis Cantarero-Mycos Research, LLC, Loveland, CO, and Dr. Innocent Mbawuike, Baylor College of Medicine, Houston, TX.
Screening the Complete TB Proteome for Protective Antigens The major goal of this project is to produce the complete TB proteome and use it to identify immunogenic candidates to develop diagnostics, therapeutics and a DNA or protein subunit vaccine against tuberculosis. Collaborators include Drs. John Belisle and Ian Orme, Colorado State University -College of Veterinary Medicine, Fort Collins, CO.
Transcriptionally Active PCR to Improve DNA Vaccines The major goal of this project is to enhance the technology developed in our Phase 1 grant (R43 AI47641-01) to screen immunogenic malaria antigens to develop candidates for diagnostics, therapeutics and a DNA or protein subunit vaccine against malaria. Collaborator is Dr. Denise Doolan, Naval Medical Research Center (NMRC), Silver Spring, MD.
Method for generating transcriptionally active DNA fragments Patent #6,280,977 Chemical modification of DNA using peptide nucleic conjugates Patent #6,165,720 Amphiphilic polyamine compounds Patent #6,433,017
GenePORTER® reagent GeneSilencer® reagent NeuroPORTER® reagent TAP Express® system TurboCells® E. coli BioPORTER® reagent
Cells and Media
Cloning and Expression